Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAT2 | Q10469 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | HRH2 | P25021 | 6/20 | 0.48 |
| ▸ | HRH1 | P35367 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7384498 | 0.82 | HRH3 (0.59) | HRH3MAOBHRH2HRH1ALDH1A1 | |
| SCHEMBL5519875 | 0.82 | HRH3 (0.62) | HRH3MAOBHRH2HRH1ALDH1A1 | |
| SCHEMBL13184922 | 0.81 | ALDH1A1 (0.51) | HRH3MAOBHRH2HRH1ALDH1A1 | |
| SCHEMBL21678030 | 0.80 | MAPT (0.50) | HRH3MAOBHRH2HRH1ALDH1A1 | |
| SCHEMBL5526919 | 0.80 | HRH3 (0.66) | HRH3MAOBHRH2HRH1ALDH1A1 | |
| SCHEMBL7387284 | 0.80 | HRH3 (0.66) | HRH3MAOBHRH2HRH1ALDH1A1 | |
| SCHEMBL7983991 | 0.80 | HRH3 (0.66) | HRH3MAOBHRH2HRH1ALDH1A1 | |
| SCHEMBL12408526 | 0.80 | HRH3 (0.66) | HRH3MAOBHRH2HRH1ALDH1A1 | |
| SCHEMBL7986752 | 0.80 | ALDH1A1 (0.66) | HRH3MAOBHRH2HRH1ALDH1A1 | |
| SCHEMBL28453675 | 0.79 | HRH3 (0.53) | HRH3MAOBHRH2HRH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4442319-A2 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| EP-4081511-B1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2024-07-31 | — | — | EP | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | MGAT2 613/4885HRH3 545/4885MAOB 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.